Susan R. Rheingold, MD

Medical School

MD - University of Pennsylvania School of Medicine, Philadelphia, PA

Internship

Pediatrics - Johns Hopkins Hospital, Baltimore MD

Residency

Pediatrics - Johns Hopkins Hospital, Baltimore MD

Fellowship

Pediatric Hematology/Oncology - The Children's Hospital of Philadelphia, Philadelphia, PA

Board Certification

Pediatric Hematology-Oncology
Pediatrics

Papers

2015

Johnson L, Leek AC, Drotar D, Noll RB, Rheingold SR, Kodish ED, Baker JN. Practical communication guidance to improve phase I informed consent conversations and end-of-life decision-making in pediatric oncology.  Cancer, 2015; epub April.

2014

Shannon ML, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 2014;371(16):1507-17.

Plourde PV, Jeha S, Hijiya N, Keller FG, Silverman LB, Rheingold SR, Dreyer ZE, Dahl GV, Mercedes T, Lai C, Corn T. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial. Pediatr Blood Cancer, 2014; 61(7):1232-8.

Maude SL, Fitzgerald JC, Fisher BT, Li Y, Huang Y-S, Torp K, Seif AE, Kavcic M, Walker DM, Leckerman KH, Kilbaugh TJ, Rheingold SR, Sung L, Zaoutis TE, Berg RA, Nadkarni VM, Thomas NJ, Aplenc RA. Outcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States. Pediatric Critical Care Medicine, 2014 15(2):112-20.

Seif AE, Fisher BT, Li Y, Torp K, Rheam DP, Huang YV, Harris T, Shah A, Hall M, Fieldston E, Vujkovic M, Bailey C, Kersun LS, Reilly AF, Rheingold SR, Walker DS, Aplenc R. Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia. Pediatr Blood Cancer, 2014;61(5):846-52.

Sacks N, Hwang W-T, Lange BJ, Tan K-S, Sandler ES, Rogers PC, Womer RB, and Rheingold SR. Proactive enteral tube feeding in pediatric patients undergoing chemotherapy. Pediatr Blood Cancer, 2014; 61(2):281-5.

2013

Lothstein K, Fisher B, Li Y, Seif AE, Harris T, Torp K, Kavcic M, Huang YS, Rheingold SR, Aplenc R. Zoonotic infections in pediatric patients with acute leukemia. Pediatr Blood Cancer, 2013;60(12):E160-2.

Baker JN, Leek AC, Showalter Salas H, Gibson D, Drotar D, Noll R, Rheingold SR, Kodish ED. Suggestions from adolescent, young adult, and parents for improving informed consent in Phase I pediatric oncology trials. Cancer, 2013;60(5):873-8.

Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Aplenc KR, Gore L, and Grupp SA. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine directed therapy. Blood, 2013;121(26):5154-7.

Borst AJ, States LJ, Reilly AF, Rheingold SR. Determining response and recurrence in pediatric B-Cell lymphomas of the bone. Pediatr Blood Cancer, 2013;60(8):1281-6.

Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med, 2013; 368(16):1509-18.

Miller VA,  Baker JN, Leek AC,  Hizlan S, Rheingold, SR, Yamokoski AD, Drotar D, Kodish E. Adolescent perspectives on Phase I cancer research. Pediatr Blood Cancer, 2013;60(5):873-78.

Abstracts

2015

Rheingold SR, Whitlock JA, Tasian SK, Teachey DT, Borowitz MJ, Lui X, Ahern CA, Minard CG, Fox E, Weigel BJ, Blaney SM. Temsirolimus and Intensive Re-induction Chemotherapy for 2nd or Greater Relapse of Acute Lymphoblastic Leukemia (ALL): a Children's Oncology Group Study (ADVL1114).  ASCO 2015

Gurunathan A, Desai AV, Bailey LC, Li Y, Choi J, Rheingold SR. Identification of patients with post-induction CNS 2 status and outcomes in acute lymphoblastic leukemia. ASCO 2015

2014

Stackelberg AV, Locatelli F, Zugmaier G, Handgretinger R, Trippet TM, Rizzari C, Zwaan CM, Bhojwani D, Dubois SG, Bader P, Borkhardt A, O’Brien MM, Rheingold SR,  Cooper TM, Hu K, Mergen N, Fischer A, Zhu M, Hijazi Y, Whitlock J, Gore L. Phase ½ study in pediatric patients with relapsed/refractory b-cell precursor acute lymphoblastic leukemia (BCP-ALL) receiving blinatumomab treatment. ASH 2014

Aplenc R, Barrett D, Callahan C, Chew A, Grupp S, June C, Lacey S, Levine B, Maude S, Melenhorst J, Motley L, Porter D, Rheingold S, Shaw P, Shen A, Teachey D, Wood P. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) have long term persistence and induce durable remissions in children with relapsed, refractory ALL. ASH 2014

Weili S, Smith A, Orgel E, Sposto R, Wilkes JJ, Gardner R, Hur Minjun, Pineros V, Olson E, Tan Y, Rheingold SR, Burke M, Wayne AS. The UK ALLR3 (R3) chemotherapy regimen for relapsed/refractory acute lymphoblastic leukemia (ALL) of childhood: A multi-institutional retrospective study of treatment related adverse events. ASH 2014

Lew G, Lu X, Yanofsky RA, Rheingold SR, Whitlock JA, An Q, Devidas M, Hastings CA, Winick NJ, Carroll WL, Borowitz MJ, Hunger SP, Pulsipher MA. Outcomes after intermediate-risk relapse of childhood B-lymphoblastic leukemia (B-ALL) and the role of allogeneic stem cell transplantation (SCT): A report from children’s oncology group (COG) AALL0433. ASH 2014

Lew G, Lu X, Yanofsky, Rheingold SR, Whitlock J, Gulig SD, Devidas M, Pulsipher M, Hastings CA, Winick NJ, Carroll WL, Borowitz MJ, Hunger S. The significance of minimal residual disease (MRD) in relapsed childhood B-lymphoblastic leukemia (B-ALL): A report from Children’s Oncology Group (COG) protocol AALL0433. ASCO 2014

Wilkes JJ, Xiao R, Seif AE, Huang YS, Vendetti ND, Rheingold SR, Aplenc R, Hennessy A, Fisher B. Variation in antibiotic use in pediatric acute lymphoblastic leukemia (ALL) by hospital pediatric volume. ASCO 2014

Whitlock J, Stackelberg AV, Handgretinger R, Locatelli F, Rizzari C, Trippett TM, Borkhardt A, O’Brien MM, Rheingold SR, Gore L. Blinatumomab in pediatric patients with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL): a phase I/II study. SIOP 2014

Grupp, S, Frey N, Aplenc R, Levine B, Maude S, Rheingold SR, Barker CS, Teachey D, Mahnke Y, Porter D, June C. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019 cells) produce significant in vivo proliferation, complete responses and long-term persistence without GVHD in children and adults with relapsed, refractory ALL. EBMT 2014

Locatelli F, Gore L, Zugmaier G, Handgretinger R, Rizzari C, Trippett TM, Borkhardt A, Rheingold SR,  Bader P, Bhojwani D, Cooper TM, DuBois SG, O’Brien MM, Zwaan CM, Holland C, Mergen N, Fischer A, Zhu M, Hijazi Y, Whitlock J, Stackelberg AV. Blinatumomab in pediatric  patients with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukaemia (BCP-ALL): a phase I/II study. EBMT  2014

2013

Grupp SA, Frey NV, Aplenc R, Barrett DM, Chew A, Kalos M, Levine BL, Lichtman M, Maude SL, Rheingold SR, Shen A, Strait C, Teachey D, Wood P, Porter D, June CH. T cells engineered with a chimeric antigen receptor (CAR) targeting CD 19 (CTL 019) produce significant in vivo proliferation, complete responses and long-term persistence without GVHD in children and adults with relapsed, refractory ALL. ASH 2013.

von Stacklberg A, Zugmaier G, Handgretinger R, Locatelli F, Rizzari C, Trippett TM, Borkhardt A, Rheingold SR, Bader P, Bhojwani D, Cooper TM, DuBois SG, O’Brien MM, Zwaan CM, Holland C, Mergen N, Fischer A, Zhu M, Hijazi Y, Whitlock J, Gore L. A phase 1/2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. ASH 2013.

von Stacklberg A, Zugmaier G, Handgretinger R, Locatelli F, Rizzari C, Trippett TM, Borkhardt A, Rheingold SR, Bader P, Bhojwani D, Cooper TM, DuBois SG, O’Brien MM, Zwaan CM, Holland C, Mergen N, Fischer A, Zhu M, Hijazi Y, Whitlock J, Gore L. A phase 1/2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. ASH 2013.

Plourde PV, Jeha S, Hijiya N, Keller F, Rheingold SR, Dreyer Z, Dahl G, Mercedes T, Corn T. Safety of asparaginase Erwinia chrysanthemi in a compassionate-use trial: Subanalysis of the adolescent/young adult (AYA) and adult patient population. ASCO 2013.

Books

Chapters

2015

Sacks N, Henry D, Rheingold SR. Oncology, Hematopoietic Transplant, Gastrointestinal Supportive Care Medications and Survivorship. In: A.S.P.E.N. Pediatric Nutrition Support Core Curriculum, 2nd Ed. M.A. Corkins ed. American Society for Parenteral and Enteral Nutrition, 2015

2013

Fisher M, Balamuth N, Rheingold SR. Basics Of Pediatric Anesthesia, In: Oncologic Diseases, 2nd Ed.,  RS Litman ed. Lippincott, Williams, and Wilkins, 2013

2012

Rheingold SR. The 5 Minute Pediatric Consult, 5th Ed. M.W. Schwartz ed.   Williams & Wilkins. Leukocytosis , Acute Lymphoblastic Leukemia, 2012

2011

Green A, Rheingold SR. Leukemia. In: Netter’s Pediatrics, 1st Ed., T Florin and S Ludwig, eds. Elsevier Health Sciences, 2011

Fisher M, Rheingold SR. Oncologic Emergencies. In: Principles and Practice of Pediatric Oncology, 6th Ed. P.A. Pizzo and D.G. Poplack eds. Lippincott, Williams, and Wilkins, 2011

Wolfe L, Scerbo J, Rheingold SR. Management of Oncologic Emergencies. In: Manual of Pediatric Hematology and Oncology, 5th Ed., P. Lanzowsky ed. Elsevier Health Sciences, 2011.

2010

Rheingold SR. Oncologic emergencies. In: Davis DH, editor. Pediatric critical care: the requisites in pediatrics. Philadelphia: Elsevier Health Sciences-Mosby.

Bailey C, Felix C, Rheingold SR. Acute lymphoblastic leukemia. In: Brodeur GM, Manno CS, editors. Pediatric hematology/oncology: the requisites in pediatrics. Philadelphia: Elsevier-Mosby.

Teachey D, Bunin N, Rheingold SR. Germ cell tumors. In: Brodeur GM, Manno CS, editors. Pediatric hematology/oncology: the requisites in pediatrics. Philadelphia: Elsevier-Mosby.

Fisher M, Rheingold SR. Oncologic emergencies. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 6th ed. Philadelphia: Lippincott, Williams and Wilkins; 2010.

Green A, Rheingold SR. Leukemia. In: Florin T, Ludwig S, editors. Netter's pediatrics. 1st ed. Philadelphia: Elsevier Health Sciences; 2010.

Wolfe L, Scerbo J, Rheingold SR. Management of oncologic emergencies. In: Lanzowsky P, editor. Manual of pediatric hematology and oncology. 5th ed. Philadelphia: Elsevier Health Sciences. 2010.

Sacks N, Wallace E, Bogucki B, Guzikowski V, Henry D, Rheingold SR. Hematology/oncology and hematopoietic transplant. In: Corkins M, editor. Pediatric nutrition support core curriculum. 1st ed. Silver Spring: American Society of Pediatric Enteral Nutrition (A.S.P.E.N.); 2010, p. 349.

2009

Rheingold SR, Neugut AI, Uldrick T, Meadows AT. Treatment-related secondary cancers. In: Hong WK, Bast RC, Hait WN, Kufe DW, Pollack RE, Weichselbaum RR, Holland JF, Frei EF, editors. Holland-Frei Cancer medicine. 8th ed. Shelton: People's Medical Publishing House; 2009. p. 1915.

2006

Rheingold SR, Neugut AI, Meadows AT. Treatment-related secondary cancers In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Hait W, Hong WK, Holland JF, Frei E, editors. Cancer medicine. 7th ed. Shelton: People's Medical Publishing House-USA; 2006.

2005

Rheingold SR, Lange BJ. Oncologic emergencies. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 5th ed. Philadelphia: Lippincott, Williams & Wilkins; 2005. p. 1202-30.

Rheingold SR, Lange BJ. Oncologic emergencies. In: Fleisher GR, Ludwig S, editors. Textbook of pediatric emergency medicine. 5th ed. Philadelphia: Lippincott, Williams & Wilkins; 2005. p. 1239-74.

Posters and Presentations

Invited Lectures

2015

"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia”, MOC Session presenter- ASPHO, Phoenix, AZ, May 2015.

Federal Drug Administration Presenter and Panelist, “New Drugs: Breakthrough Therapies and Beyond”- AACR, Philadelphia, PA, April 2015.

2014

Session Moderator, “What’s all the Buzz about Targeted Immunotherapies for B-Cell Malignancies”- ASPHO, Chicago, IL, May 2014.

2013

“Pediatric ALL: Update on Treatment and Follow-up Care” - Leukemia & Lymphoma Society Telephone/Web Education Program, National Teleconference, November 2013.

“A Phase 1 Study of Temsirolimus in Combination with Etoposide & Cyclophosphamide in Children with Relapsed ALL and NHL” - Therapeutic Advances in Childhood Leukemia Annual Meeting, Chicago, IL, September 2013.

“The First Five ALL Patients Treated with Chimeric Antigen Receptor-Modified T-cells (CART)” - ALL Study Chair Affinity Group, International Teleconference, May 2013.

“Childhood Cancer” - Congreso Interamericano de Pediatria, Starmedica Conference, Mexico City, Mexico, January 2013.